3350.F AADI BIOSCIENCES DL-0001

Healthcare Biotechnology Frankfurt Exchange
2.70 EUR
Close of Nov 11, 2026
1.66 4.26
Market cap
EUR 159M
P/E
-
P/B
1.10x
ROE
-49.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 3350.F undervalued?

Graham number

The Graham number of AADI BIOSCIENCES DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AADI BIOSCIENCES DL-0001 fundamental analysis

No fundamental analysis for AADI BIOSCIENCES DL-0001 yet.

AADI BIOSCIENCES DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AADI BIOSCIENCES DL-0001

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Full company profile